Research ExplorerPublicationsClinical implications of molecular drug resistance testing f...

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Standard

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. / Domínguez, José; Boeree, Martin J; Cambau, Emmanuelle; Chesov, Dumitru; Conradie, Francesca; Cox, Vivian; Dheda, Keertan; Dudnyk, Andrii; Farhat, Maha R; Gagneux, Sebastien; Grobusch, Martin P; Gröschel, Matthias I; Guglielmetti, Lorenzo; Kontsevaya, Irina; Lange, Berit; van Leth, Frank; Lienhardt, Christian; Mandalakas, Anna M; Maurer, Florian P; Merker, Matthias; Miotto, Paolo; Molina-Moya, Barbara; Morel, Florence; Niemann, Stefan; Veziris, Nicolas; Whitelaw, Andrew; Horsburgh, Charles R; Lange, Christoph; TBnet and RESIST-TB networks.

In: LANCET INFECT DIS, Vol. 23, No. 4, 04.2023, p. e122-e137.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Domínguez, J, Boeree, MJ, Cambau, E, Chesov, D, Conradie, F, Cox, V, Dheda, K, Dudnyk, A, Farhat, MR, Gagneux, S, Grobusch, MP, Gröschel, MI, Guglielmetti, L, Kontsevaya, I, Lange, B, van Leth, F, Lienhardt, C, Mandalakas, AM, Maurer, FP, Merker, M, Miotto, P, Molina-Moya, B, Morel, F, Niemann, S, Veziris, N, Whitelaw, A, Horsburgh, CR, Lange, C & TBnet and RESIST-TB networks 2023, 'Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement', LANCET INFECT DIS, vol. 23, no. 4, pp. e122-e137. https://doi.org/10.1016/S1473-3099(22)00875-1

APA

Domínguez, J., Boeree, M. J., Cambau, E., Chesov, D., Conradie, F., Cox, V., Dheda, K., Dudnyk, A., Farhat, M. R., Gagneux, S., Grobusch, M. P., Gröschel, M. I., Guglielmetti, L., Kontsevaya, I., Lange, B., van Leth, F., Lienhardt, C., Mandalakas, A. M., Maurer, F. P., ... TBnet and RESIST-TB networks (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. LANCET INFECT DIS, 23(4), e122-e137. https://doi.org/10.1016/S1473-3099(22)00875-1

Vancouver

Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. LANCET INFECT DIS. 2023 Apr;23(4):e122-e137. https://doi.org/10.1016/S1473-3099(22)00875-1

Bibtex

@article{df40f69ff1124b8cacd9139668c77634,
title = "Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement",
abstract = "Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.",
keywords = "Humans, Mycobacterium tuberculosis/genetics, Microbial Sensitivity Tests, Antitubercular Agents/pharmacology, Tuberculosis, Multidrug-Resistant/diagnosis, Tuberculosis/drug therapy, Mutation",
author = "Jos{\'e} Dom{\'i}nguez and Boeree, {Martin J} and Emmanuelle Cambau and Dumitru Chesov and Francesca Conradie and Vivian Cox and Keertan Dheda and Andrii Dudnyk and Farhat, {Maha R} and Sebastien Gagneux and Grobusch, {Martin P} and Gr{\"o}schel, {Matthias I} and Lorenzo Guglielmetti and Irina Kontsevaya and Berit Lange and {van Leth}, Frank and Christian Lienhardt and Mandalakas, {Anna M} and Maurer, {Florian P} and Matthias Merker and Paolo Miotto and Barbara Molina-Moya and Florence Morel and Stefan Niemann and Nicolas Veziris and Andrew Whitelaw and Horsburgh, {Charles R} and Christoph Lange and {TBnet and RESIST-TB networks}",
note = "Copyright {\textcopyright} 2023 Elsevier Ltd. All rights reserved.",
year = "2023",
month = apr,
doi = "10.1016/S1473-3099(22)00875-1",
language = "English",
volume = "23",
pages = "e122--e137",
journal = "LANCET INFECT DIS",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "4",

}

RIS

TY - JOUR

T1 - Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

AU - Domínguez, José

AU - Boeree, Martin J

AU - Cambau, Emmanuelle

AU - Chesov, Dumitru

AU - Conradie, Francesca

AU - Cox, Vivian

AU - Dheda, Keertan

AU - Dudnyk, Andrii

AU - Farhat, Maha R

AU - Gagneux, Sebastien

AU - Grobusch, Martin P

AU - Gröschel, Matthias I

AU - Guglielmetti, Lorenzo

AU - Kontsevaya, Irina

AU - Lange, Berit

AU - van Leth, Frank

AU - Lienhardt, Christian

AU - Mandalakas, Anna M

AU - Maurer, Florian P

AU - Merker, Matthias

AU - Miotto, Paolo

AU - Molina-Moya, Barbara

AU - Morel, Florence

AU - Niemann, Stefan

AU - Veziris, Nicolas

AU - Whitelaw, Andrew

AU - Horsburgh, Charles R

AU - Lange, Christoph

AU - TBnet and RESIST-TB networks

N1 - Copyright © 2023 Elsevier Ltd. All rights reserved.

PY - 2023/4

Y1 - 2023/4

N2 - Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.

AB - Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the TBnet and RESIST-TB networks, about reporting standards for the clinical use of molecular drug susceptibility testing. Review and the search for evidence included hand-searching journals and searching electronic databases. The panel identified studies that linked mutations in genomic regions of M tuberculosis with treatment outcome data. Implementation of molecular testing for the prediction of drug resistance in M tuberculosis is key. Detection of mutations in clinical isolates has implications for the clinical management of patients with multidrug-resistant or rifampicin-resistant tuberculosis, especially in situations when phenotypic drug susceptibility testing is not available. A multidisciplinary team including clinicians, microbiologists, and laboratory scientists reached a consensus on key questions relevant to molecular prediction of drug susceptibility or resistance to M tuberculosis, and their implications for clinical practice. This consensus document should help clinicians in the management of patients with tuberculosis, providing guidance for the design of treatment regimens and optimising outcomes.

KW - Humans

KW - Mycobacterium tuberculosis/genetics

KW - Microbial Sensitivity Tests

KW - Antitubercular Agents/pharmacology

KW - Tuberculosis, Multidrug-Resistant/diagnosis

KW - Tuberculosis/drug therapy

KW - Mutation

U2 - 10.1016/S1473-3099(22)00875-1

DO - 10.1016/S1473-3099(22)00875-1

M3 - SCORING: Review article

C2 - 36868253

VL - 23

SP - e122-e137

JO - LANCET INFECT DIS

JF - LANCET INFECT DIS

SN - 1473-3099

IS - 4

ER -